Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cutting edge: New chimeric NOD2/TLR2 adjuvant drastically increases vaccine immunogenicity.

Journal of immunology (Baltimore, Md. : 1950) - 15 Dec 2014

Pavot Vincent, Rochereau Nicolas, Rességuier Julien, Gutjahr Alice, Genin Christian, Tiraby Gerard, Perouzel Eric, Lioux Thierry, Vernejoul Fabienne, Verrier Bernard, Paul Stéphane

Abstract excerpt

TLR ligands are critical activators of innate immunity and are being developed as vaccine adjuvants. However, their usefulness in conjunction with NOD-like receptor agonists remains poorly studied. In this study, we evaluated a new ligand that targets both TLR2 and NOD2 receptors. We assessed its ability to enhance dendritic cell maturation in vitro in addition to improving systemic and mucosal immune responses...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to HIV Core Protein p24

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunity, Mucosal

Share to Immunoglobulin A

Share to Lipopeptides

Share to Nod2 Signaling Adaptor Protein

Share to Toll-Like Receptor 2

Share to Vaccines

Source

Identifiers

PMID: 25392526
DOI: 10.4049/jimmunol.1402184

Genes

NOD2
TLR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cutting edge: New chimeric NOD2/TLR2 adjuvant drastically increases vaccine immunogenicity.PMID 25392526Read ↗

Cutting Edge: A Dual TLR2 and TLR7 Ligand Induces Highly Potent Humoral and Cell-Mediated Immune ResponsesSemantic proximity Read ↗

Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvantsSemantic proximity Read ↗

Nod2-Dependent Th2 Polarization of Antigen-Specific ImmunitySemantic proximity Read ↗

Utilizing murine dendritic cell line DC2.4 to evaluate the immunogenicity of subunit vaccines in vitroSemantic proximity Read ↗

Identification of a synthetic muramyl peptide derivative with enhanced Nod2 stimulatory capacity.Semantic proximity Read ↗

Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity.Semantic proximity Read ↗

CCL17 production by dendritic cells is required for NOD1-mediated exacerbation of allergic asthma.Semantic proximity Read ↗

The role of TLR2 in cutaneous leishmaniasis and as a target for vaccine adjuvantsSemantic proximity Read ↗

Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity.Semantic proximity Read ↗

Linked Toll-Like Receptor Triagonists Stimulate Distinct, Combination-Dependent Innate Immune ResponsesSemantic proximity Read ↗

Screening and Identification of a Chicken Dendritic Cell Binding Peptide by Using a Phage Display LibrarySemantic proximity Read ↗

Enhanced immune response induced by P5 HER2/neu-derived peptide-pulsed dendritic cells as a preventive cancer vaccine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.